中国报告大厅网讯,在全球医药产业加速变革的背景下,中国创新药企正以突破性进展改写行业版图。2024年数据显示,百济神州凭借全球首个同类最优BTK抑制剂实现药品销售收入272.14亿元,超越恒瑞医药成为A股市值最高的医药企业,这一里程碑事件折射出中国医药产业从仿制跟随到全球创新的跨越式发展。 一、全球制药50强榜单新势力:百济神州的崛起与医药创新模式转型,市场分析及医药投资分析 中国报告大厅发布...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.